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S U M M A R Y
Objectives: We aimed to investigate trends in the prevalence of multidrug-resistant tuberculosis (MDR-
TB) among Chinese people from ﬁrst report to 2006, and to detect the high prevalence regions in order to
guide control efforts.
Materials and methods: The CBM, VIP, CNKI, and MEDLINE databases were searched through both
keywords and subject headings. The literature was screened, and two investigators assessed the quality
and extracted the data. Trends inMDR-TB prevalence in three groups – primary, acquired, and combined
MDR-TB – were examined separately, using the Cochran–Armitage trend test. Differences were tested
with the Kruskal–Wallis test. High prevalence provinces were explored through comparison of the 95%
conﬁdence interval (95% CI) with the national average level.
Results: Overall 169 studies were included, with 165 in Chinese and four in English. One hundred and
sixteen studies concerned primary MDR-TB, 103 acquired MDR-TB, and 130 combined MDR-TB, with
total positive Mycobacterium tuberculosis (MTB) isolates of 110 076, 25 187, and 150 233, respectively.
The prevalences of MDR-TB in the three groups in 2005 were 2.64-, 6.20-, and 3.84-times that of 1985,
respectively, all showing an upward trend (p < 0.05). The prevalences among the three groups were
signiﬁcantly different (p < 0.05), with acquired drug resistance (27.5%, 95% CI 26.9–28.1%) much higher
than primary drug resistance (4.3%, 95% CI 4.2–4.4%), and combined resistance (9.9%, 95% CI 9.8–10.1%)
in between. The top three prevalence regions for primary, acquired, and combined MDR-TB were
distributed in the zone from the northeast to the southwest of China, with Hebei, Tibet, and Shanxi
having an extremely high prevalence.
Conclusions: The prevalence of MDR-TB among the Chinese people has shown an upward trend since
1985. It is necessary to continue to monitor this trend in China. Special attention should be paid to
provinces distributed in the zone from the northeast to the southwest of China for MDR-TB surveillance,
research, and control.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In 2005, China ranked second behind India in the estimated
number of tuberculosis (TB) incident cases, and multidrug-
resistant tuberculosis (MDR-TB) was shown to be higher among
new and previously treated cases in China than in India.1 An
estimated 489 139 MDR-TB cases emerged in 2006, with China,
India and the Russian Federation carrying the highest numbers;
China and India carried approximately 50% of the global burden
and the Russian Federation a further 7%. In terms of the proportion
of MDR-TB among all TB cases, China ranked second behind the* Corresponding author. Tel.: +86 28 85423040; fax: +86 28 85422253.
E-mail address: ccebm@126.com (Y.-p. Li).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.02.2244Russian Federation, however in absolute numbers, China had the
highest burden of cases in the world.2
Four large-scale cross-sectional surveys were carried out in
China in 1979, 1985, 1990, and 2000 and the ﬁfth national survey
will be carried out in 2010. The surveys provide basic data for
program development and evaluation. It has been reported in
China that from 1979 to 2000, the prevalence of active pulmonary
TB decreased from 717/100 000 to 346/100 000 and the prevalence
of sputum smear-positive pulmonary TB decreased from 187/
100 000 to 110/100 000.3 However, with regard to the magnitude
of drug resistance, the information has been limited; for example,
365 097 specimens were investigated in 2000 with only 392
Mycobacterium tuberculosis (MTB) isolates analyzed for drug
resistance; the prevalences of MDR-TB among new, previously
treated, and combined cases were 7.6%, 17.1%, and 10.7%,
respectively.3ses. Published by Elsevier Ltd. All rights reserved.
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International Union Against Tuberculosis and Lung Disease (WHO/
IUATLD) Global Project on Anti-Tuberculosis Drug Resistance
Surveillance (WHO Project) since 1996 with a small number of
provinces/areas involved one after another; the information has
just been for that local area in the survey year. However, it is
necessary to understand national MDR-TB prevalence. Hence we
collected all relevant studies to analyze the trends among Chinese
people in order to provide basic information for MDR-TB control.
Materials and methods
Data sources
The Chinese CBM, VIP, and CNKI databases and the English
MEDLINE database were searched through both keywords and
subject headings. The keywords included Mycobacterium tubercu-
losis, drug resistance, multi-drug resistance, drug-resistant tuber-
culosis, multidrug-resistant tuberculosis, microbial susceptibility
tests, and anti-mycobacterial susceptibility tests. The subject
headings included Mycobacterium tuberculosis; drug resistance,
multiple; tuberculosis, multidrug-resistant; microbial sensitivity
tests; and drug resistance, bacterial. For MEDLINE, additional
restrictions (China/Chinese/Hong Kong/Macao/Taiwan) were ap-
plied to limit objects to the Chinese people. All the databases were
searched up to December 2006.
Study selection
Studies were eligible for inclusion if MDR-TB was correctly
deﬁned or the results of anti-mycobacterial susceptibility tests
were reported clearly for each anti-tuberculosis drug, including at
least rifampin (R) and isoniazid (H). The identiﬁcation of
pulmonary TB was based on clinical symptoms, the results of
chest X-ray, etiological detection, and pathological examination;4
the improved Lowenstein–Jensen culture medium and absolute
concentration indirect method for susceptibility tests were used in
the studies.5
MDR-TB was deﬁned as a TB case who had MTB resistant to at
least R and H. Primary MDR-TB was deﬁned as an MDR-TB case
who had never been treated or who had been treated for less than
one month with anti-tuberculosis drugs. Acquired MDR-TB was
deﬁned as an MDR-TB case who had been treated with anti-
tuberculosis drugs for no less than onemonth. CombinedMDR-TB
was deﬁned as an MDR-TB case regardless of the treatment
history.
As previously reported,6 China has a nationwide information
system for disease control and prevention to which the diagnosed
TB patient is reported by the clinician; the clinician has the
responsibility of making sure that the information is complete,
including the treatment history of the identiﬁed TB patient. We
included the combined group in addition to the primary and
acquired MDR-TB groups, to take account of quite a few papers in
which susceptibility tests were carried out and the results were
reported without consideration of patient treatment history.
Studies were excluded from the analysis if the total number of
culture-positive MTB cases was not reported and/or it was not
possible to retrieve the number of MDR-TB cases and/or the tests
were carried out only for speciﬁc populations, such as the elderly,
children, prisoners, etc.
Quality assessment
Seven items were developed to assess the quality of included
studies, based on the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement.7,8 The items were:(1) whether the recruitment time of the objects was reported; (2)
whether the recruitment place of the objects was reported; (3)
whether the source of the data (e.g., medical records, diseases
reporting system, survey, etc.) was reported; (4) whether the
deﬁnition of MDR-TB was clear; (5) whether the procedures for
anti-mycobacterial susceptibility testing were reported; (6)
whether the object was of hospital origin or population origin;
and (7) whether primary and acquired MDR-TB were deﬁned
properly. Items 1–6 were determined for all studies, whereas item
7 was only assessed for those studies reporting primary and
acquired MDR-TB separately. If the answer was ‘yes’ for items 1–5
and item 7, a score of ‘1’ was assigned, if the answer was ‘no’, a
score of ‘0’ was assigned. For item 6, if the object was population
origin then it got a score of ‘1’ and if it was of hospital origin it got a
score of ‘0’. The mean average score for each region was calculated
and the region graded accordingly (A to E in decreasing quality).
Quality control
Two investigators were independently responsible for quality
assessment and data extraction; if there was disagreement, a
discussion to agreement would follow; if this failed, a third party
was invited to make the judgment.
Statistical analyses
MDR-TB prevalence (the statistical indicator) was deﬁned as
the proportion of MDRMTB isolates to the total number of culture-
positive MTB over a certain period of time (e.g., 1 year), which
equaled the number of MDR MTB isolates divided by the total
number of culture-positiveMTB, times 100%.We calculated this for
the three groups of primary, acquired, and combined MDR-TB
cases based on the literature reports. Data from the included
studies carried out in the same region (special administrative
region (SAR)/autonomous region (AR)/ municipality/province)
were pooled.
Trends in MDR-TB prevalence in the three groups were
examined separately using the Cochran–Armitage trend test.
Differences in the prevalence of MDR-TB in the three groups were
tested by Kruskal–Wallis test. High prevalence regions were
explored through comparison of the 95% conﬁdence interval (95%
CI) with the national average level. A p-value of less than 0.05 was
used to denote statistical signiﬁcance. SPSS 13.0, Excel 2003 and
CorelDRAW 12 software packages were used for the analyses.
Results
One hundred and sixty-nine studies9–177 were included, with
165 in Chinese and four in English (Figure 1).
The quality assessment results are shown in Table 1. Most
areas located in the southwest, the north, and central China got
low scores in the item totals, with Tibet the lowest. These are
relatively less developed areas, demonstrating the gap in study
report quality between the less developed and more developed
areas of China.
One hundred and sixteen studies reported on primary MDR-TB,
103 on acquired MDR-TB, and 130 on combined drug resistance
(data not shown), with totals of 110 076, 25 187, and 150 233
culture-positive MTB cases, respectively (Table 2). The earliest
report was seen in 1981. It was not until 1985 that drug
susceptibility test studies were reported consecutively in China.
The number of positive MTB isolates varied over the period 1985–
2006, with medians of 4795, 936, and 6666 for primary, acquired,
and combined MDR-TB, respectively. There were more isolates in
1995–2004 compared to other periods (with themost in 1999 in all
groups); this decreased after 2004, and the least for all groupswere
Figure 1. Flow chart of document retrieval and selection.
Table 1
Evaluation of the included studies in 28 provinces/regions
Items 1–6 Item 7
Province/region Mean Ranka Province/region M
Hong Kong 6.00 A Hong Kong 1
Guangdong 5.03 B Taiwan 1
Taiwan 5.00 B Ningxia 1
Ningxia 5.00 B Guangxi 1
Guizhou 5.00 B Zhejiang 0
Guangxi 5.00 B Liaoning 0
Gansu 5.00 B Hunan 0
Henan 4.75 C Shandong 0
Zhejiang 4.70 C Yunnan 0
Liaoning 4.67 C Xinjiang 0
Hubei 4.67 C Tianjin 0
Beijing 4.67 C Shanghai 0
Fujian 4.62 C Inner Mongolia 0
Sichuan 4.60 C Guangdong 0
Shanghai 4.50 C Fujian 0
Hunan 4.38 D Sichuan 0
Tianjin 4.33 D Shanxi 0
Shandong 4.33 D Jiangsu 0
Jiangsu 4.27 D Jilin 0
Shanxi 4.25 D Beijing 0
Hebei 4.17 D Henan 0
Yunnan 4.00 D Hubei 0
Xinjiang 4.00 D Shanxi 0
Shanxi 4.00 D Tibet 0
Inner Mongolia 4.00 D Hebei 0
Jilin 4.00 D Guizhou 0
Anhui 4.00 D Anhui 0
Tibet 3.50 E Gansu N
NA: Not applicable.
Special Administrative Region (SAR): Hong Kong; Autonomous Region (AR): Ningxia (H
Mongolia (Mongolian) and Tibet (Tibetan nationality); Municipality: Beijing, Shanghai
a A (=6.00), B (5.00 and <6.00), C (4.50 and <5.00), D (4.00 and <4.50), E (<4.0
b A (=1.00), B (0.60 and <1.00), C (0.45 and <0.60), D (>0 and <0.45), E (=0).
c Sum of mean of items 1–6 and item 7.
d A (5.50), B (5.00 and <5.50), C (4.50 and <5.00), D (4.00 and <4.50), E (0<4
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groups, respectively) (Table 2).
The culture-positive MTB totals for 1981–2006 in the different
regions are shown in Figure 2. The top ﬁve regions were Hong
Kong, Guangdong, Fujian, Henan, and Shanghai. With the
exception of Henan, the other four are developed areas. Figure 2
reﬂects the great variation in reported culture-positive MTB in the
different regions of China.
Trends in MDR-TB prevalence
Figure 3 shows the trends in MDR-TB prevalence of primary,
acquired, and combined MDR-TB among Chinese people (national
and local).
National
Description
Figure 3 shows that the primary MDR-TB prevalence remained
below 4.0% before 1995, then increased gradually reaching 6.1% in
1996, then ﬂuctuated upwards. It was higher than 4.0% after 1999
and reached 10.0% after 2005. A more signiﬁcant rise was seen in
2006 than in 2005, with an increase of 44%.
The combined MDR-TB prevalence was stable below 5.0%
before 1989; in 1990 it reached 15.9%, then ﬂuctuated upwards to
19.1% in 2005, reaching 31.6% in 2006 (an increase of 65% from
2005 to 2006).
The acquired MDR-TB prevalence ﬂuctuated upwards to reach
32.4% during 1985–1990 and was then around 30.0% until 2005; a
noticeable increase to 51.0% then occurred in 2006 (an increase of
66% from 2005 to 2006).Items 1–7
ean Rankb Province/region Meanc Rankd
.00 A Hong Kong 7.00 A
.00 A Taiwan 6.00 A
.00 A Ningxia 6.00 A
.00 A Guangxi 6.00 A
.78 B Zhejiang 5.48 B
.67 B Guangdong 5.48 B
.67 B Liaoning 5.34 B
.60 B Hunan 5.05 B
.50 C Fujian 5.04 B
.50 C Shanghai 5.00 B
.50 C Henan 5.00 B
.50 C Guizhou 5.00 B
.50 C Beijing 5.00 B
.45 C Sichuan 4.93 C
.42 D Shandong 4.93 C
.33 D Hubei 4.89 C
.33 D Tianjin 4.83 C
.33 D Jiangsu 4.60 C
.33 D Shanxi 4.58 C
.33 D Yunnan 4.50 C
.25 D Xinjiang 4.50 C
.22 D Inner Mongolia 4.50 C
.17 D Jilin 4.33 D
.00 E Shanxi 4.17 D
.00 E Hebei 4.17 D
.00 E Anhui 4.00 D
.00 E Tibet 3.50 E
A NA Gansu NA NA
ui nationality), Guangxi (Zhuang nationality), Xinjiang (Uygur nationality), Inner
and Tianjin; Province: others.
0).
.00).
Table 2
Culture-positive MTB and MDR-TB isolates among Chinese people, 1981–2006
Year Primary Acquired Combined
Culture-positive (N) MDR-TB (n) Culture-positive (N) MDR-TB (n) Culture-positive (N) MDR-TB (n)
1981 232 1
1982
1983 301 1
1984
1985 1644 65 1472 73 2931 146
1986 2221 66 399 54 2620 120
1987 3554 90 371 42 3802 131
1988 2679 75 435 61 2961 119
1989 2670 58 245 41 2761 99
1990 4052 73 776 251 6507 1032
1991 4683 96 887 271 5264 360
1992 4468 92 328 73 4182 120
1993 6172 138 934 378 6825 650
1994 6011 143 1039 248 7383 453
1995 5645 154 318 58 5448 278
1996 7530 459 1900 601 12 149 1315
1997 7575 257 1422 349 10 466 616
1998 5673 124 654 104 8483 439
1999 9873 475 3881 1291 14 474 1751
2000 3990 226 1301 364 8179 810
2001 7466 616 1706 616 9951 1615
2002 9232 446 1811 458 11 882 1156
2003 4906 437 2399 802 8937 1292
2004 6391 286 1754 392 9546 1178
2005 2621 273 938 288 4039 772
2006 487 73 217 111 1443 456
Total 110 076 4724 25 187 6926 150 233 14 909
MTB, Mycobacterium tuberculosis; MDR-TB, multidrug-resistant tuberculosis.
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Drug susceptibility tests were reported consecutively after
1985 and the number of culture-positive MTB was the least in all
groups in 2006. Hencewe carried out statistical testing of the trend
for 1985–2005 to show the time distribution of MDR-TB
prevalence during the 20-year period in China, and compared it
among the three groups to test the differences.
The trends
The primary MDR-TB prevalence showed a signiﬁcant upward
trend of 2.64-fold in 2005 compared with 1985 (p < 0.05). We
further tested this for the 1980s, 1990s, and 2000s; the downward
trend in 1985–1990 (p < 0.05) and the upward trend in 1991–2000
(p < 0.05) were signiﬁcant, but the trend in 2001–2005 was not
signiﬁcant (p = 0.95).
The combined MDR-TB prevalence showed an upward trend of
3.84-fold in 2005 compared with 1985 (p < 0.05). Trends over the
same three time periods (1980s, 1990s, and 2000s) were all
signiﬁcantly upward with p < 0.05, p < 0.05, and p = 0.01, respec-
tively.
The acquired MDR-TB prevalence showed an upward trend of
6.20-fold in 2005 compared with 1985 (p < 0.05). The trend was
signiﬁcant in 1985–1990 (upward, p < 0.05), not signiﬁcant in
1991–2000 (p = 0.98), and signiﬁcant in 2001–2005 (downward,
p < 0.05).
Comparison among the three groups
The prevalence in the primary, acquired, and combinedMDR-TB
groups was signiﬁcantly different (p < 0.05). The weighted mean
prevalence of MDR-TB was 4.3% (95% CI 4.2–4.4%) for primary,
27.5% (95% CI 26.9–28.1%) for acquired, and 9.9% (95% CI 9.8–
10.1%) for combined MDR-TB. Comparisons between primary and
acquired, and primary and combined, and acquired and combinedall showed signiﬁcant differences (p < 0.05 for each comparison).
This demonstrates a wide gap between primary and acquired
MDR-TB prevalence, with the latter much higher, and combined
prevalence in between.
Local
Hebei, Shanxi, and Tibet were the provinces/regions with the
greatest burden of primary, combined, and acquired MDR-TB,
respectively (see below in the section on spatial distribution), and
the trends in these areas are plotted in Figure 3.
The available data points show that the prevalence of MDR-TB
was higher in these regions compared to the national level except
for Shanxi in 2006.
The test of statistical signiﬁcance indicated that the trend in
primary MDR-TB in Hebei was upwards (p < 0.05), and the trends
in combined MDR-TB in Shanxi and of acquired MDR-TB in Tibet
were not signiﬁcant (p = 0.11 and 0.70, respectively).
Spatial distribution
Figures 4, 5, and 6 show comparisons of MDR-TB prevalence in
the different regions over the period 1981–2006 for primary,
acquired, and combined MDR-TB. The x-axis represents the
different regions and the y-axis represents MDR-TB prevalence
(primary in Figure 4, acquired in Figure 5, and combined in
Figure 6). The national data total is to the far right of the x-axis and
the horizontal line across the national data total represents the
average magnitude of MDR-TB prevalence in China. The circle is
the point estimation of MDR-TB prevalence for the region, and the
upper end of the vertical line through the circle is the upper limit of
the 95% CI for corresponding MDR-TB prevalence and the lower
end is the lower limit of the 95% CI.
Figure 4 shows that the regions having a primary MDR-TB
prevalence higher than the national level (4.3%) were Hebei
Figure 2. Positive MDR isolates in 28 provinces/regions, 1981–2006.
Figure 3. Trends in MDR-TB prevalence among Chinese people (national and high-burden local).
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Figure 4. Comparison of primary MDR-TB prevalence among 25 regions, 1981–
2006.
Figure 6. Comparison of combined MDR-TB prevalence among 27 regions, 1985–
2006.
Figure 7. Comparison of primary MDR-TB prevalence with national level, 1981–
2006.
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Guizhou, Jilin, Liaoning, Shandong, Sichuan, Jiangsu, and Guang-
dong (the only province in the southeast of China with a higher
prevalence), p < 0.05, with point estimates of the prevalence in
descending order. Provinces 1 (Hunan) to 5 (Zhejiang) had the
lower prevalences (p < 0.05), with Hunan the lowest (0.9%). For AR
6 (Xinjiang) to province 10 (Fujian) and AR 16 (InnerMongolia) and
municipality 17 (Tianjin), prevalence was not different from the
national average level (p > 0.05).
Figure 5 shows that the regions having an acquired MDR-TB
prevalence higher than the national level (27.5%) were Tibet
(77.4%), Shanxi (54.9%), Sichuan (53.9%), Inner Mongolia, Ningxia,
Hebei, Henan, Tianjin, Shanxi, Guizhou, Jilin, Beijing, and
Shandong; p < 0.05, with the point estimate of prevalence in
descending order. SAR 1 (Hong Kong) to province 7 (Hunan) had
lower prevalences (p < 0.05), with Hong Kong the lowest (11.9%).
For provinces 8 (Yunnan) to 14 (Hubei), prevalence was not
different from the national average level (p > 0.05).
Figure 6 shows that the regions having a combined MDR-TB
prevalence higher than the national level (9.9%) were province 11
(Anhui) to AR 14 (Guangxi) and provinces 16 (Shandong) to 27
(Shanxi) (p < 0.05), among which Shanxi (37.1%), Ningxia (29.6%),
Jilin (28.8%), Jiangsu, Guizhou, Sichuan, Hebei, Shanxi, InnerFigure 5. Comparison of acquired MDR-TB prevalence among 27 regions, 1985–
2006.
Figure 8. Comparison of acquired MDR-TB prevalence with national level, 1985–
2006.
Figure 9. Comparison of combined MDR-TB prevalence with national level, 1985–
2006.
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the prevalence in descending order) had much higher prevalences
(p < 0.05). SAR 1 (Hong Kong) to province 5 (Zhejiang), province 7
(Guangdong) andmunicipality 8 (Shanghai) had lower prevalences
(p < 0.05), with Hong Kong the lowest (2.5%). Provinces 6 (Gansu),
9 (Fujian), 10 (Hubei), and 15 (Yunnan) had combined MDR-TB
prevalence not different from the national average level (p > 0.05).
Figures 7, 8, and 9 are maps showing the results of Figures 4, 5,
and 6, respectively.
Regions with the top three MDR-TB prevalences in the three
groups were Jilin, Hebei, Henan, Ningxia, Shanxi, Sichuan, and
Tibet, which are distributed in the zone from the northeast to the
southwest of China. Hebei, Tibet, and Shanxi had extremely high
prevalences of primary, acquired, and combined MDR-TB, respec-
tively.
Discussion
The disparity between economically developed and other
developing/underdeveloped regions in the quality assessment of
reports reﬂects the gap in scientiﬁc research between them. A
strengthening of personnel development in health facilities of less
developed areas is urgently required to improve their daily work
and research capability (planning and reporting), in order to gain
better control of this widespread disease.
The primary, acquired, and combined MDR-TB prevalences for
2005 were 2.64-, 6.20-, and 3.84-times those of 1985, respectively,
and increased signiﬁcantly in all groups during this period.
China has been involved in theWHOProject since 1996. Overall,
the pooledMDR-TB prevalences are in agreementwith the ﬁndings
of the WHO Project, however there are differences in some years.
The WHO Project in China has not been a countrywide survey and
the number of provinces involved has varied from one (years 1997,
2001, 2002, and 2004) to four (years 1999 and 2005), with far
fewer culture-positiveMTB isolates in theWHOProject than in this
review (12 894 vs. 110 076 of primary, 2277 vs. 25 187 of acquired,
and 16 087 vs. 150 233 of combinedMDR-TB cases).2 Thismight, to
some extent, have contributed to the differences. The number of
positive MTB isolates in 2006 was the lowest during the period
1985–2006, which may be attributed to the lag between study
completion and publication. There are risks of biased data in 2006
because of the small sample size, and it is necessary to follow up on
the trends in recent years in order to better understand the
epidemiology and results of efforts made to ﬁght this disease,especially after 1990 in China. In 1996, the Chinese government
enhanced TB control by changing its classiﬁcation from a category
C to a category B infectious disease (more strict requirements for
infectious disease reporting, prevention and control in the disease
prevention and treatment system for category B than C), and has
recently paid special attention to ﬁghting the three major
infectious diseases of TB, hepatitis B, and AIDS in the community.
The prevalences in the three groupswere signiﬁcantly different,
demonstrating the gap between primary and acquired MDR-TB
prevalence. The magnitude of acquired MDR-TB is seriously high
and implies an association between drug resistance and the
therapeutic process. Primary MDR-TB deserves special focus, as it
may result in resistance to pyrazinamide and ethambutol178 and
even an outbreak of MDR-TB.179 It is reasonable that the combined
prevalence is between the prevalences for primary and acquired
MDR-TB, as it is the MDR-TB prevalence among cases regardless of
treatment history (all cases).
Extremely drug-resistant TB (XDR-TB) is deﬁned as TB with
resistance to at least R and H, and resistance to a ﬂuoroquinolone
and a second-line injectable agent. This has been reported in China
in several local special hospitals over the recent ﬁve years.
However, according to a WHO report there are no data on XDR-TB
for 2002–2007 at the national level.2 A national survey of drug
resistance was carried out in China during 2007–2008, however
the ﬁnal report is not yet available.
Guangdong is the only province in the southeast that had a
higher primary MDR-TB prevalence than the national average
level. This may be related to human migration, as Guangdong is
located in the densest ﬂoating population area of China.180 The top
three prevalence provinces in the threeMDR-TB groups are located
in the zone from the northeast to the southwest of China, which are
less developed areas compared to the southeast of China. Among
them, Henan, Sichuan, and Hebei are populous provinces and
Henan has a high burden of AIDS.181 Tibet (Tibetan AR), is located
in the southwest border area of China and has a plateau terrain. Our
previous study suggested a high incidence of TB clustering in the
Tibetan autonomous area in Sichuan Province;6 the association
between TB incidence and MDR-TB prevalence in the Tibetan
nationality is a topic worth further exploration. Ningxia is an AR
inhabited by those of Hui nationality; Shanxi is inland and amulti-
ethnic province of China. Jilin is located in the northernmost part of
the temperate zone and the northeast border area of China. Results
suggest that there is an urgent need to focus on detection and
prevention in high-risk people, intensive TB casemanagement, and
environmental disinfection in these regions.
The spatial distribution revealed in our study suggests that the
prevalence of MDR-TB may be related to geography, although the
evidence is not sufﬁcient at present. And in China, the geography,
apart from geographical position, is represented by factors such as
economic development, population density and mobility, propor-
tionof ethnicminorities and their characteristics, anddistributionof
relevant diseases (for example, AIDS), which should be addressed in
future research to improve the management of MDR-TB.
In the 1990s, the directly observed treatment, short-course
(DOTS) strategy was implemented step by step in China. It was
reported that the Chinese government expended greater effort and
higher budgets towards the lagging provinces to achieve nation-
wide TB control targets,182 and that the rate of DOTS coverage to
counties increased from 68% in 2001 to 100% in 2005.183 Is
variation in the progress of DOTS implementation including drug
supply to the different areas statistically signiﬁcant? If it is, what is
the magnitude of the effect on MDR-TB prevalence? Further
investigations are needed.
Our study has limitations. Eligible published reports were not
available for all of the 34 provinces/municipalities/ARs/SARs, not
every study explored MDR-TB in all three investigated groups, and
X.-y. Yang et al. / International Journal of Infectious Diseases 14 (2010) e828–e837 e835therewere variations in the sumof culture-positiveMTB isolates in
the different regions and years. However, without long-term
nationwide surveillance data, the results obtained here are so far
the best source to show the magnitude of MDR-TB prevalence
among the Chinese people in the past. The limitations should spur
others to carry out further prospective studies to include the
collection of high quality epidemiological and microbiological
surveillance data, the monitoring of trends in MDR-TB, and the
detection of key localities or groups of people for further research
and better control in the future.
In conclusion, the prevalence of primary, acquired, and
combined MDR-TB showed an upward trend from 1985 to 2005
among Chinese people. It is necessary to continue to monitor
trends in MDR-TB prevalence, and special attention should be paid
to regions distributed in the zone from the northeast to the
southwest of China for MDR-TB surveillance, research, and control.
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